Conditionally Active
Biologics: Transforming
Cancer Therapy
Corporate Presentation
May 2024
Important Notices & Disclaimers
This presentation (the "Presentation") by BioAtla, Inc. ("we", "us", "our", "BioAtla", or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to statements regarding business plans and prospects and whether our clinical trials will support registration; achievement of milestones; results, conduct, progress and timing of our research and development programs and clinical trials; expectations with respect to enrollment and dosing in our clinical trials, plans and expectations regarding future data updates, clinical trials, regulatory meetings and regulatory submissions; plans to form collaborations or other strategic partnerships for selected assets; the potential regulatory approval path for our product candidates; expectations about the sufficiency of our cash and cash equivalents to fund operations. Words such as, but not limited to, "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "potential", "predict", "project", "should", "will", "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, identify forward-looking statements.
These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Presentation and are subject to risks and uncertainties, including those described in the Company's filings with the SEC, including but not limited to the Company's latest Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q. Moreover, the Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for management to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The Company qualifies all the forward-looking statements in this Presentation by these cautionary statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Statements contained herein are made as of the date of this Presentation unless stated otherwise, and this Presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that the information will be updated or revisited to reflect information that subsequently becomes available or changes occurring after that date hereof.
Certain information contained in this Presentation relates to or is based on statistical and other industry and market data obtained from independent industry publications and research, surveys and studies conducted by independent third parties as well as the Company's own estimates of the prevalence of certain diseases and conditions. The market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. The Company's estimates of the patient population with the potential to benefit from treatment with any product candidates the Company may develop include several key assumptions based on its industry knowledge, industry publications and third-party research, which may be based on a small sample size and may fail to accurately reflect the addressable patient population. While the Company believes that its internal assumptions are reasonable, no independent source has verified such assumptions.
This Presentation may contain trademarks, trade names, or service marks belonging to other entities. The Company does not intend the use or display of other parties' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of, or by these other parties.
None of the Company or any of its directors, officers, employees, contractors, agents, consultants, advisors or other representatives makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained in this Presentation.
BioAtla | Overview 2
Bioatla© Is A Clinical Stage Company Focused On Transforming Cancer Therapy
with Conditionally Active Biologics (CABs)
Two Phase 2 CAB-ADCs, one | |
Proprietary technology | Phase 2 CAB-CTLA-4 and one |
Phase 1 dual CAB-bispecific T- | |
Broad applicability in solid | cell engager |
tumors | Mecbotamab vedotin |
Increases therapeutic | advancing potentially |
window | registrational trial in |
Undifferentiated Pleomorphic | |
Sarcoma (UPS) |
Clinical readouts for multiple indications / assets through 2024
Advancing strategic
collaboration discussions
$80.6 million in cash and cash
equivalents as of 03/31/24
Cash position sufficient into
2H 2025
BioAtla | Overview 3
Leadership Team
Jay Short, Ph.D. | Richard Waldron, M.B.A. | Eric Sievers, M.D. | Sheri Lydick |
Chairman, CEO and Cofounder | Chief Financial Officer | Chief Medical Officer | Chief Commercial Officer |
GeneMedicine, Inc. | |||
Bin Zhang, M.D. | William Boyle, Ph.D. | Monica Sullivan | Susie Melody |
Sr. VP, Clinical Development. | Sr. Research Fellow | Sr. VP, Intellectual Property & Contracts | Sr. VP, Human Resources |
CapaIP |
BioAtla | Overview 4
Board of Directors and Scientific Advisors
Jay Short, Ph.D. | |||
Chairman, Chief Executive | Mary Ann Gray, Ph.D. | Sylvia McBrinn | Susan Moran, MD, MSCE |
Officer & Cofounder | Director | Director | Director |
Director |
Scott Smith | Lawrence Steinman, MD | Eddie Williams |
Director | Director | Director |
James Allison, Ph.D. | Lawrence Fong, MD |
Cancer Immunotherapy | |
MD Anderson Cancer Center | |
Program, UCSF | |
Scientific Advisor | |
Scientific Advisor | |
Padmanee Sharma, MD, Ph.D. | Michael Manyak, MD |
MD Anderson Cancer Center | GlaxoSmithKline |
Scientific Advisor | Scientific Advisor |
BioAtla | Overview 5
Selective And Targeted CAB Technology Widens Therapeutic Window
Thus has the potential to enhance clinical outcomes in multiple tumor types
BioAtla discovered that acidic pH at the cancer cell surface unveils binding sites that are shielded at normal pH of healthy cells
BioAtla invented CAB technology, creating antibodies that bind only to these unveiled sites on cancer cells
CAB binding region is not masked or caged and thus different from prodrugs that require irreversible enzymatic cleavage to become activated
CAB antibodies have the potential for increased efficacy with improved safety relative to traditional antibodies
Alkaline Healthy Cell Membrane | Acidic Cancer Cell Membrane | |
No CAB Binding | CAB Binding |
H+ | |
H+ H+ | |
H+ | |
H+ | H+ |
H+ | H+ |
H+ | |
H+ |
Chang, H.W., Frey, G., Liu, H., Xing, C., Steinman, L, Boyle, B.J., & Short, J.M. (2021) PNAS 118(9): 1-10, Suppl. 1-19.
BioAtla | Overview 6
Broad Applicability Of BioAtla's CAB Platform Across Several Antibody Types
I/O Antibodies | ADCs |
Target: CTLA-4 | Targets: ROR2, AXL |
CTLA-4 blockade activates effector | Widely expressed in a variety of tumor |
T cells, thereby enhancing anti- | types, ROR2 and AXL overexpression |
tumor immunity | correlates with poor prognosis, |
metastasis, and drug resistance to PD-1 | ||||||||
and EGFR therapies | ||||||||
CAB-CTLA4 | CAB-CTLA4 | |||||||
CAB-Tumor Cell Target | ||||||||
Cytotoxic payload | ||||||||
and linker |
Bispecific TCE
Target: EpCAM & CD3
Bispecific antibodies bridge cancer cells and cytotoxic T lymphocytes, activating T cells and promoting cancer cell lysis
Tumor Cell Target
CAB-EpCAM
T Cell Target | CAB-CD3 |
ADC - antibody drug conjugate; IO - immuno-oncology; TCE - T-cell engager | BioAtla | Overview 7 |
Focused Pipeline with Broad Applicability of Differentiated CAB Assets Designed to Deliver Near-term value
CAB Program
Target
Indications
IND Enabling Pre-Clinical
Phase 1 Clinical
Phase 2 Clinical
Mecbotamab Vedotin | AXL | UPS | ||
NSCLC | ||||
CAB-ADCs | ||||
Ozuriftamab Vedotin | ROR2 | Melanoma | ||
SCCHN | ||||
Melanoma | ||||
CAB-I/O | Evalstotug | CTLA-4 | NSCLC | |
Carcinomas | ||||
CAB- | BA3182 | EpCAM x CD3 | Adenocarcinomas | |
Bispecific TCE | ||||
Next Gen | BA3361 | Nectin-4 | Multiple tumor types | |
CAB-ADC | ||||
IND, investigational new drug; UPS, Undifferentiated Pleomorphic Sarcoma; NSCLC, Non-small Cell Lung Cancer; SCCHN, Squamous Cell Carcinoma of the Head and Neck | BioAtla | Overview 8 |
Evalstotug (CAB-CTLA-4): Basket Trial
CAB-CTLA4 Selectively Active in Tumor Microenvironment, Thereby Reducing Immune Related Adverse Events (irAEs)
Severe irAEs | Minimized irAEs | |||||||||
Non-CABCTLA-4 | Normal Cell (alkaline) | CAB CTLA-4 | ||||||||
inhibitors | Tumor selective binding | |||||||||
anti-CTLA4 | anti-CTLA4 | CAB-anti-CTLA4 | CAB-anti-CTLA4 | |||||||
Cancer cell (acidic) |
Cytotoxic (CD8+) T cells
T regulatory cells
Normal Cell | Normal Cell |
BioAtla | Overview 10
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
BioAtla Inc. published this content on 14 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 May 2024 20:08:10 UTC.